Prolonged Pregnancy Following Long-Term Celecoxib Use in a Case of Uterine Adenomyosis: A Case Report

case-report OA: closed public-domain-us
Full text JSON View on PubMed View at publisher
AI-generated summary by claude@2026-06, 2026-06-08

A case report details how celecoxib and ritodrine successfully managed pain and contractions in a pregnant patient with uterine adenomyosis, prolonging the pregnancy until a cesarean section was performed.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-06, 2026-06-08 · read from full text

This case report describes a 37-year-old primiparous woman with uterine adenomyosis who experienced severe pain and threatened preterm labor in the second trimester and was treated with celecoxib (a COX-2 inhibitor) plus ritodrine. The combination reduced symptoms and was associated with prolongation of pregnancy, but labor began shortly after celecoxib was discontinued at 28 weeks, leading to an emergency cesarean section; the neonate had no significant complications and the patient’s pain resolved postpartum. The authors note that, despite the apparent effectiveness, further studies are needed to assess long-term safety. This paper is centrally about adenomyosis — it reports celecoxib use for pain and threatened preterm labor in a pregnancy complicated by uterine adenomyosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) are generally avoided in late pregnancy due to fetal risks, such as premature ductus arteriosus closure. However, celecoxib, a selective cyclooxygenase 2 (COX-2) inhibitor, may help manage pain and uterine contractions with fewer adverse effects. Here, we report a case of a 37-year-old primiparous woman with uterine adenomyosis who was treated with celecoxib and ritodrine hydrochloride for severe pain and threatened preterm labor in the second trimester. This combination effectively reduced symptoms, allowing prolongation of pregnancy. However, labor commenced shortly after discontinuation of celecoxib at 28 weeks of gestation, requiring an emergency cesarean section. The neonate had no significant complications, and the patient's pain resolved postpartum. This case demonstrates that celecoxib can be a viable option for managing pain and contractions in pregnancy complicated by adenomyosis; however, further studies are needed to assess its long-term safety.
Full text 1,583 characters · extracted from oa-doi-fallback · click to expand
Prolonged Pregnancy Following Long-Term Celecoxib Use in a Case of Uterine Adenomyosis: A Case Report Funding: The authors received no specific funding for this work. ABSTRACT Nonsteroidal anti-inflammatory drugs (NSAIDs) are generally avoided in late pregnancy due to fetal risks, such as premature ductus arteriosus closure. However, celecoxib, a selective cyclooxygenase 2 (COX-2) inhibitor, may help manage pain and uterine contractions with fewer adverse effects. Here, we report a case of a 37-year-old primiparous woman with uterine adenomyosis who was treated with celecoxib and ritodrine hydrochloride for severe pain and threatened preterm labor in the second trimester. This combination effectively reduced symptoms, allowing prolongation of pregnancy. However, labor commenced shortly after discontinuation of celecoxib at 28 weeks of gestation, requiring an emergency cesarean section. The neonate had no significant complications, and the patient's pain resolved postpartum. This case demonstrates that celecoxib can be a viable option for managing pain and contractions in pregnancy complicated by adenomyosis; however, further studies are needed to assess its long-term safety. Conflicts of Interest Dr. Takeda Jun is an Editorial Board member of the JOGR Journal and a co-author of this article. To minimize bias, they were excluded from all editorial decision-making related to the acceptance of this article for publication. Data Availability Statement Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

adenomyosis

MeSH descriptors

Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Celecoxib Celecoxib Celecoxib Celecoxib Celecoxib Celecoxib Celecoxib Celecoxib Celecoxib Celecoxib Cyclooxygenase 2 Inhibitors Cyclooxygenase 2 Inhibitors

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
pubmed
last seen: 2026-06-02T00:30:52.586114+00:00
unpaywall
last seen: 2026-05-11T08:34:28.763810+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine